Cargando…

Enrichment and Liquid Chromatography–Mass Spectrometry Analysis of Trastuzumab and Pertuzumab Using Affimer Reagents

[Image: see text] Trastuzumab and pertuzumab are monoclonal antibodies used in the treatment of human epidermal growth factor receptor-2 (HER2)-positive breast cancer. Therapeutic proteins may undergo chemical modifications that may affect the results of bioanalytical assays, as well as their therap...

Descripción completa

Detalles Bibliográficos
Autores principales:	Olaleye, Oladapo, Spanov, Baubek, Ford, Robert, Govorukhina, Natalia, van de Merbel, Nico C., Bischoff, Rainer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Chemical Society 2021
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8515351/ https://www.ncbi.nlm.nih.gov/pubmed/34582688 http://dx.doi.org/10.1021/acs.analchem.1c02807

Ejemplares similares

Determination of Binding Sites on Trastuzumab and Pertuzumab to Selective Affimers Using Hydrogen–Deuterium Exchange Mass Spectrometry
por: Olaleye, Oladapo, et al.
Publicado: (2023)

Effect of Trastuzumab–HER2 Complex Formation on Stress-Induced Modifications in the CDRs of Trastuzumab
por: Spanov, Baubek, et al.
Publicado: (2022)

Pertuzumab Charge Variant Analysis and Complementarity-Determining Region Stability Assessment to Deamidation
por: Spanov, Baubek, et al.
Publicado: (2023)

Revealing charge heterogeneity of stressed trastuzumab at the subunit level
por: Spanov, Baubek, et al.
Publicado: (2023)

Non-Antibody-Based Binders for the Enrichment of Proteins for Analysis by Mass Spectrometry
por: Olaleye, Oladapo, et al.
Publicado: (2021)

Affimer proteins are versatile and renewable affinity reagents
por: Tiede, Christian, et al.
Publicado: (2017)

Affimer reagents as tools in diagnosing plant virus diseases
por: Hesketh, Emma L., et al.
Publicado: (2019)

Identification and Characterization of an Affimer Affinity Reagent for the Detection of the cAMP Sensor, EPAC1
por: Buist, Hanna K., et al.
Publicado: (2021)

Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer
por: Bianchini, Giampaolo, et al.
Publicado: (2017)

Affimer proteins for F-actin: novel affinity reagents that label F-actin in live and fixed cells
por: Lopata, Anna, et al.
Publicado: (2018)

Characterization of infections and hypogammaglobulinemia treated with the combination of pertuzumab and trastuzumab
por: Mortimer, Joanne E., et al.
Publicado: (2019)

Skin/nail infections with the addition of pertuzumab to trastuzumab-based chemotherapy
por: Mortimer, Joanne, et al.
Publicado: (2014)

Cryo-EM Structure of HER2-trastuzumab-pertuzumab complex
por: Hao, Yue, et al.
Publicado: (2019)

BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer
por: Dang, Chau, et al.
Publicado: (2022)

Selection and characterisation of Affimers specific for CEA recognition
por: Shamsuddin, Shazana Hilda, et al.
Publicado: (2021)

Affimers and nanobodies as molecular probes and their applications in imaging
por: Cordell, Paul, et al.
Publicado: (2022)

Pertuzumab Increases 17-AAG-Induced Degradation of ErbB2, and This Effect Is Further Increased by Combining Pertuzumab with Trastuzumab
por: Hughes, Juliana Bentes, et al.
Publicado: (2012)

Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer
por: Sims, A H, et al.
Publicado: (2012)

In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma
por: El-Sahwi, K, et al.
Publicado: (2010)

The Effects of Pertuzumab and Its Combination with Trastuzumab on HER2 Homodimerization and Phosphorylation
por: Nami, Babak, et al.
Publicado: (2019)

Correction: Cryo-EM Structure of HER2-trastuzumab-pertuzumab complex
por: Hao, Yue, et al.
Publicado: (2019)

Trastuzumab Associated With Recurrent Severe Thrombocytopenia and Successful Use of Pertuzumab Monotherapy
por: Huff, Mallorie L, et al.
Publicado: (2022)

Pruritus Related to Trastuzumab and Pertuzumab in HER2+ Breast Cancer Patients
por: Gu, Stephanie, et al.
Publicado: (2023)

Exploiting nanobodies and Affimers for superresolution imaging in light microscopy
por: Carrington, Glenn, et al.
Publicado: (2019)

Affimers as an Alternative to Antibodies in an Affinity LC–MS Assay for Quantification of the Soluble Receptor of Advanced Glycation End-Products (sRAGE) in Human Serum
por: Klont, Frank, et al.
Publicado: (2018)

Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models
por: Veeraraghavan, Jamunarani, et al.
Publicado: (2021)

Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2(+) breast cancer in the adaptively randomized I-SPY2 trial
por: Clark, Amy S., et al.
Publicado: (2021)

Binding Affinity of Trastuzumab and Pertuzumab Monoclonal Antibodies to Extracellular HER2 Domain †
por: Cruz, Victor L., et al.
Publicado: (2023)

Combination efficacy of pertuzumab and trastuzumab for trastuzumab emtansine-resistant cells exhibiting attenuated lysosomal trafficking or efflux pumps upregulation
por: Yamashita-Kashima, Yoriko, et al.
Publicado: (2020)

Comparative Effectiveness and Safety of Pertuzumab and Trastuzumab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy for Treatment of Metastatic Breast Cancer
por: Dai, Wei Fang, et al.
Publicado: (2022)

Ovarian cancer with high-level focal ERBB2 amplification responds to trastuzumab and pertuzumab
por: Thouvenin, Laure, et al.
Publicado: (2021)

Pertuzumab in Combination with Trastuzumab and Docetaxel in the Neoadjuvant Treatment for HER2-Positive Breast Cancer
por: Vieira, Cláudia, et al.
Publicado: (2022)

A Membrane‐Permeable and Immobilized Metal Affinity Chromatography (IMAC) Enrichable Cross‐Linking Reagent to Advance In Vivo Cross‐Linking Mass Spectrometry
por: Jiang, Pin‐Lian, et al.
Publicado: (2022)

Development of an Affimer-antibody combined immunological diagnosis kit for glypican-3
por: Xie, Chunmei, et al.
Publicado: (2017)

Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer
por: Nami, Babak, et al.
Publicado: (2018)

A search for synergy in the binding kinetics of Trastuzumab and Pertuzumab whole and F(ab) to Her2
por: Lua, Wai-Heng, et al.
Publicado: (2015)

Tumor lysis syndrome following trastuzumab and pertuzumab for metastatic breast cancer: a case report
por: Baudon, C., et al.
Publicado: (2016)

Development and validation of an LC-MS/MS method for simultaneous quantification of co-administered trastuzumab and pertuzumab
por: Schokker, Sandor, et al.
Publicado: (2020)

Association of Pertuzumab, Trastuzumab, and Docetaxel Combination Therapy With Overall Survival in Patients With Metastatic Breast Cancer
por: Ramagopalan, Sreeram V., et al.
Publicado: (2021)

Cardiotoxicity after Additional Administration of Pertuzumab following Long-Term Trastuzumab: Report of 2 Cases
por: Ito, Mayuko, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5jpd27nkv7d0grsjse3hdcqpc6